{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:02:27Z","timestamp":1782903747748,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-025-07419-5","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:07:47Z","timestamp":1761570467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of enalapril and losartan on the expression of genes involved in inflammation, fibrogenesis, and apoptosis in orbital fibroblasts of graves\u2019 ophthalmopathy"],"prefix":"10.1186","volume":"18","author":[{"given":"Fatemeh","family":"Sanie-Jahromi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Owji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"2","key":"7419_CR1","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168\u201399.","journal-title":"Endocr Rev"},{"issue":"5","key":"7419_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","volume":"292","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Tanda ML. Current concepts regarding graves\u2019 orbitopathy. J Intern Med. 2022;292(5):692\u2013716.","journal-title":"J Intern Med"},{"key":"7419_CR3","doi-asserted-by":"publisher","first-page":"1217253","DOI":"10.3389\/fphar.2023.1217253","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhao Q, Li B. Current and promising therapies based on the pathogenesis of graves\u2019 ophthalmopathy. Front Pharmacol. 2023;14:1217253. https:\/\/doi.org\/10.3389\/fphar.2023.1217253.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7419_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ajo.2006.02.047","volume":"142","author":"JA Garrity","year":"2006","unstructured":"Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142(1):147\u201353.e142.","journal-title":"Am J Ophthalmol"},{"key":"7419_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.exer.2015.02.007","volume":"142","author":"WA Dik","year":"2016","unstructured":"Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of graves\u2019 ophthalmopathy. Exp Eye Res. 2016;142:83\u201391.","journal-title":"Exp Eye Res"},{"issue":"3","key":"7419_CR6","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.survophthal.2021.08.010","volume":"67","author":"V Gupta","year":"2022","unstructured":"Gupta V, Hammond CL, Roztocil E, Gonzalez MO, Feldon SE, Woeller CF. Thinking inside the box: current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease. Surv Ophthalmol. 2022;67(3):858\u201374.","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"7419_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1089\/thy.2007.0407","volume":"18","author":"GM Lehmann","year":"2008","unstructured":"Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid. 2008;18(9):959\u201365.","journal-title":"Thyroid"},{"key":"7419_CR8","doi-asserted-by":"crossref","unstructured":"Bouzehouane N, Borson-Chazot F, Abeillon J, Caron P. Treatment of moderate to severe orbitopathy: current modalities and perspectives. In: Annales d\u2019Endocrinologie: 2021. Elsevier: 92\u20138.","DOI":"10.1016\/j.ando.2021.02.001"},{"issue":"3","key":"7419_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.beem.2011.11.005","volume":"26","author":"C Marcocci","year":"2012","unstructured":"Marcocci C, Marin\u00f2 M. Treatment of mild, moderate-to-severe and very severe graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):325\u201337.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"7419_CR10","doi-asserted-by":"crossref","unstructured":"Bartalena L. Role of teprotumumab in the treatment of active moderate-to-severe graves\u2019 orbitopathy. Eur Thyroid J 2022, 11(6).","DOI":"10.1530\/ETJ-22-0185"},{"key":"7419_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1590\/2359-3997000000252","volume":"61","author":"LC Delfino","year":"2017","unstructured":"Delfino LC, Zunino A, Sapia V, Croome MCS, Ilera V, Gauna AT. Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with graves\u2019 disease. Archives Endocrinol Metabolism. 2017;61:374\u201381.","journal-title":"Archives Endocrinol Metabolism"},{"key":"7419_CR12","doi-asserted-by":"crossref","unstructured":"Zeng P, Fan S-x, Li Z-j, Peng Y-y, Hu Y-x, Xu M-t, Wang M. Evaluation of the graves\u2019 Orbitopathy-specific quality of life questionnaire in the mainland Chinese population. Journal of Ophthalmology. 2019, 2019.","DOI":"10.1155\/2019\/7602419"},{"issue":"2\u20133","key":"7419_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0014-2999(99)00031-X","volume":"368","author":"M K\u00e4h\u00f6nen","year":"1999","unstructured":"K\u00e4h\u00f6nen M, Tolvanen J-P, Kalliovalkama J, Wu X, Karjala K, M\u00e4kynen H, P\u00f6rsti I. Losartan and Enalapril therapies enhance vasodilatation in the mesenteric artery of spontaneously hypertensive rats. Eur J Pharmacol. 1999;368(2\u20133):213\u201322.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"7419_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0002-9343(83)91198-1","volume":"75","author":"E Silverstein","year":"1983","unstructured":"Silverstein E, Schussler GC, Friedland J. Elevated serum angiotensin-converting enzyme in hyperthyroidism. Am J Med. 1983;75(2):233\u20136.","journal-title":"Am J Med"},{"issue":"6","key":"7419_CR15","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1007\/s10787-023-01335-5","volume":"31","author":"YH Habib","year":"2023","unstructured":"Habib YH, Sheta E, Khattab M, Gowayed MA. Hyaluronic acid\/diminazene aceturate combination ameliorates Osteoarthritic anomalies in a rodent model: a role of the ACE2\/Ang1-7\/MasR axis. Inflammopharmacology. 2023;31(6):3263\u201379.","journal-title":"Inflammopharmacology"},{"issue":"4","key":"7419_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/jcm10040702","volume":"10","author":"IG Rajapaksha","year":"2021","unstructured":"Rajapaksha IG, Gunarathne LS, Angus PW, Herath CB. Update on new aspects of the renin-angiotensin system in hepatic fibrosis and portal hypertension: implications for novel therapeutic options. J Clin Med. 2021;10(4):702.","journal-title":"J Clin Med"},{"issue":"1","key":"7419_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/jc.2006-1824","volume":"92","author":"T Cawood","year":"2007","unstructured":"Cawood T, Moriarty P, O\u2019Farrelly C, O\u2019shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metabolism. 2007;92(1):59\u201364.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"7419_CR18","doi-asserted-by":"crossref","unstructured":"Sanie-Jahromi F, Nowroozzadeh MH, Shaabanian M, Khademi B, Owji N, Mehrabani D. Characterization of central and nasal orbital adipose stem cells and their neural differentiation footprints. Curr Stem Cell Res Therapy 2023.","DOI":"10.2174\/1574888X19666230905114246"},{"issue":"1","key":"7419_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/app11010417","volume":"11","author":"B Saravi","year":"2021","unstructured":"Saravi B, Li Z, Pfannkuche J, Wystrach L, H\u00e4ckel S, Albers E, Grad C, Alini S, Richards M, Lang RG. Angiotensin II type 1 receptor antagonist Losartan inhibits TNF-\u03b1-induced inflammation and degeneration processes in human nucleus pulposus cells. Appl Sci. 2021;11(1):417.","journal-title":"Appl Sci"},{"issue":"1","key":"7419_CR20","doi-asserted-by":"publisher","first-page":"24801","DOI":"10.1038\/s41598-024-76657-7","volume":"14","author":"JH Majolo","year":"2024","unstructured":"Majolo JH, Gon\u00e7alves JI, Souza RP, Gonz\u00e1lez LC, Sperotto N, Silveira MD, Oliveira SD, Bizarro CV, Machado P, Basso LA. Losartan and Enalapril maleate differently influence SARS-CoV-2-infected Vero cells. Sci Rep. 2024;14(1):24801.","journal-title":"Sci Rep"},{"issue":"4","key":"7419_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/HYPERTENSIONAHA.109.132886","volume":"54","author":"K Kappert","year":"2009","unstructured":"Kappert K, Tsuprykov O, Kaufmann J, Fritzsche J, Ott I, Goebel M, B\u00e4hr IN, H\u00e4\u00dfle P-L, Gust R, Fleck E. Chronic treatment with Losartan results in sufficient serum levels of the metabolite EXP3179 for PPAR\u03b3 activation. Hypertension. 2009;54(4):738\u201343.","journal-title":"Hypertension"},{"issue":"3","key":"7419_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0749-0704(05)70333-X","volume":"13","author":"DD Vernon","year":"1997","unstructured":"Vernon DD, Gleich MC. Poisoning and drug overdose. Crit Care Clin. 1997;13(3):647\u201367.","journal-title":"Crit Care Clin"},{"issue":"1","key":"7419_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/thy.2012.0373","volume":"23","author":"R Botta","year":"2013","unstructured":"Botta R, Lisi S, Marcocci C, Sellari-Franceschini S, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Sisti E. Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts. Thyroid. 2013;23(1):92\u20136.","journal-title":"Thyroid"},{"key":"7419_CR24","doi-asserted-by":"publisher","first-page":"952954","DOI":"10.3389\/fimmu.2022.952954","volume":"13","author":"J Zheng","year":"2022","unstructured":"Zheng J, Duan H, You S, Liang B, Chen Y, Huang H. Research progress on the pathogenesis of graves\u2019 ophthalmopathy: based on immunity, noncoding RNA and exosomes. Front Immunol. 2022;13:952954.","journal-title":"Front Immunol"},{"issue":"44","key":"7419_CR25","doi-asserted-by":"publisher","first-page":"28395","DOI":"10.1039\/D2RA04340H","volume":"12","author":"EM Bezerra","year":"2022","unstructured":"Bezerra EM, de Alvarenga \u00c9C, Dos Santos RP, de Sousa JS, Fulco UL, Freire VN, Albuquerque EL, da Costa RF. Losartan as an ACE inhibitor: a description of the mechanism of action through quantum biochemistry. RSC Adv. 2022;12(44):28395\u2013404.","journal-title":"RSC Adv"},{"key":"7419_CR26","unstructured":"Herman LL, Padala SA, Ahmed I, Bashir K. Angiotensin-converting enzyme inhibitors (ACEI). 2017."},{"key":"7419_CR27","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/00004872-199507001-00002","volume":"13","author":"PK Siegl","year":"1995","unstructured":"Siegl PK, Kivlighn SD, Broten TP. Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. J Hypertens. 1995;13:S15\u201321.","journal-title":"J Hypertens"},{"key":"7419_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cellsig.2018.07.011","volume":"51","author":"R Bernasconi","year":"2018","unstructured":"Bernasconi R, Nystr\u00f6m A. Balance and circumstance: the Renin angiotensin system in wound healing and fibrosis. Cell Signal. 2018;51:34\u201346.","journal-title":"Cell Signal"},{"issue":"29","key":"7419_CR29","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.2174\/092986709789178046","volume":"16","author":"F Xu","year":"2009","unstructured":"Xu F, Mao C, Hu Y, Rui C, Xu Z, Zhang L. Cardiovascular effects of Losartan and its relevant clinical application. Curr Med Chem. 2009;16(29):3841\u201357.","journal-title":"Curr Med Chem"},{"issue":"2","key":"7419_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.0022-202x.2001.01409.x","volume":"117","author":"M Raisova","year":"2001","unstructured":"Raisova M, Hossini AM, Eberle J, Riebeling C, Orfanos CE, Geilen CC, Wieder T, Sturm I, Daniel PT. The Bax\/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95\/Fas-mediated apoptosis. J Invest Dermatology. 2001;117(2):333\u201340.","journal-title":"J Invest Dermatology"},{"key":"7419_CR31","unstructured":"Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2\/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. In: Seminars in cancer biology: 1993. 327\u2013332."},{"issue":"11","key":"7419_CR32","first-page":"4079","volume":"84","author":"LA Kaback","year":"1999","unstructured":"Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1\u03b2 in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metabolism. 1999;84(11):4079\u201384.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"1","key":"7419_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","volume":"100","author":"JJ Khong","year":"2016","unstructured":"Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142\u201350.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"7419_CR34","first-page":"7453260","volume":"2019","author":"D \u0141acheta","year":"2019","unstructured":"\u0141acheta D, Mi\u015bkiewicz P, G\u0142uszko A, Nowicka G, Struga M, Kantor I, Po\u015blednik KB, Mirza S, Szczepa\u0144ski MJ. Immunological aspects of graves\u2019 ophthalmopathy. Biomed Res Int. 2019;2019(1):7453260.","journal-title":"Biomed Res Int"},{"issue":"1","key":"7419_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1210\/en.2005-1018","volume":"147","author":"R Han","year":"2006","unstructured":"Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1\u03b2 in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology. 2006;147(1):13\u20139.","journal-title":"Endocrinology"},{"issue":"37","key":"7419_CR36","doi-asserted-by":"publisher","first-page":"22718","DOI":"10.1074\/jbc.271.37.22718","volume":"271","author":"H-S Wang","year":"1996","unstructured":"Wang H-S, Cao HJ, Winn VD, Rezanka LJ, Frobert Y, Evans CH, Sciaky D, Young DA, Smith TJ. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts: an in vitro model for connective tissue inflammation. J Biol Chem. 1996;271(37):22718\u201328.","journal-title":"J Biol Chem"},{"issue":"3","key":"7419_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2249.1998.00613.x","volume":"112","author":"G F\u00f6rster","year":"1998","unstructured":"F\u00f6rster G, Otto E, Hansen C, Ochs K, Kahaly G. Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Experimental Immunol. 1998;112(3):427\u201334.","journal-title":"Clin Experimental Immunol"},{"issue":"2","key":"7419_CR38","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","volume":"175","author":"B Chen","year":"2005","unstructured":"Chen B, Tsui S, Smith TJ. IL-1\u03b2 induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol. 2005;175(2):1310\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"7419_CR39","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0002-9440(10)63488-8","volume":"163","author":"L Koumas","year":"2003","unstructured":"Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol. 2003;163(4):1291\u2013300.","journal-title":"Am J Pathol"},{"issue":"2","key":"7419_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U","volume":"32","author":"L Koumas","year":"2002","unstructured":"Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1\u2009+\u2009and Thy\u20101\u2010subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002;32(2):477\u201385.","journal-title":"Eur J Immunol"},{"issue":"2","key":"7419_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1006\/cimm.1996.0268","volume":"173","author":"MA Borrello","year":"1996","unstructured":"Borrello MA, Phipps RP. Differential Thy-1 expression by Splenic fibroblasts defines functionally distinct subsets. Cell Immunol. 1996;173(2):198\u2013206.","journal-title":"Cell Immunol"},{"issue":"12","key":"7419_CR42","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1089\/thy.2008.0255","volume":"18","author":"TK Khoo","year":"2008","unstructured":"Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS. Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with graves\u2019 ophthalmopathy. Thyroid. 2008;18(12):1291\u20136.","journal-title":"Thyroid"},{"key":"7419_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fbioe.2020.00392","volume":"8","author":"M Hao","year":"2020","unstructured":"Hao M, Sun J, Zhang Y, Zhang D, Han J, Zhang J, Qiao H. Exploring the role of SRC in extraocular muscle fibrosis of the graves\u2019 ophthalmopathy. Front Bioeng Biotechnol. 2020;8:392.","journal-title":"Front Bioeng Biotechnol"},{"key":"7419_CR44","doi-asserted-by":"publisher","first-page":"607968","DOI":"10.3389\/fendo.2020.607968","volume":"11","author":"Y-H Wei","year":"2021","unstructured":"Wei Y-H, Liao S-L, Wang S-H, Wang C-C, Yang C-H. Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of graves\u2019 ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways. Front Endocrinol. 2021;11:607968.","journal-title":"Front Endocrinol"},{"issue":"6","key":"7419_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/medicina57060621","volume":"57","author":"E Kardalas","year":"2021","unstructured":"Kardalas E, Maraka S, Papagianni M, Paltoglou G, Siristatidis C, Mastorakos G. TGF-\u03b2 physiology as a novel therapeutic target regarding autoimmune thyroid diseases: where do we stand and what to expect. Medicina. 2021;57(6):621.","journal-title":"Medicina"},{"issue":"3","key":"7419_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1089\/thy.2022.0254","volume":"33","author":"Y Lu","year":"2023","unstructured":"Lu Y, Wang Y, Wang Y, Wu Y, Huang Y, Liu X, Zhang S, Zhong S, Li Y, Li B. M1-Like macrophages modulate fibrosis and inflammation of orbital fibroblasts in graves\u2019 orbitopathy: potential relevance to soluble Interleukin-6 receptor. Thyroid. 2023;33(3):338\u201350.","journal-title":"Thyroid"},{"issue":"9","key":"7419_CR47","doi-asserted-by":"publisher","first-page":"339","DOI":"10.9734\/jammr\/2024\/v36i95581","volume":"36","author":"BE da Silva Oliveira","year":"2024","unstructured":"da Silva Oliveira BE, Guimar\u00e3es GF, Coutinho IJB, Gouveia EHH, Moraes ECDS, D\u2019Ara\u00fajo Filho JJS, Oliveira AKA, Fayal SP, Maia CC. Zemeroa\u2009+\u2009MIM: systematic review of Losartan eye drops in managing Post-Surgical corneal haze. J Adv Med Med Res. 2024;36(9):339\u201350.","journal-title":"J Adv Med Med Res"},{"issue":"9","key":"7419_CR48","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/ICO.0000000000003527","volume":"43","author":"EG Rodgers","year":"2024","unstructured":"Rodgers EG, Al-Mohtaseb Z, Chen AJ. Topical Losartan for treating corneal haze after ultraviolet-A\/riboflavin collagen cross-linking. Cornea. 2024;43(9):1165\u201370.","journal-title":"Cornea"},{"key":"7419_CR49","doi-asserted-by":"publisher","first-page":"109884","DOI":"10.1016\/j.exer.2024.109884","volume":"242","author":"SE Wilson","year":"2024","unstructured":"Wilson SE. Two-phase mechanism in the treatment of corneal stromal fibrosis with topical Losartan. Exp Eye Res. 2024;242:109884.","journal-title":"Exp Eye Res"},{"key":"7419_CR50","doi-asserted-by":"publisher","first-page":"109631","DOI":"10.1016\/j.exer.2023.109631","volume":"235","author":"TM Shiju","year":"2023","unstructured":"Shiju TM, Sampaio LP, Martinez VV, Hilgert GS, Wilson SE. Transforming growth factor beta-3 localization in the corneal response to epithelial-stromal injury and effects on corneal fibroblast transition to myofibroblasts. Exp Eye Res. 2023;235:109631.","journal-title":"Exp Eye Res"},{"issue":"11","key":"7419_CR51","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3928\/1081597X-20221018-02","volume":"38","author":"AL Pereira-Souza","year":"2022","unstructured":"Pereira-Souza AL, Ambr\u00f3sio R Jr, Bandeira F, Salom\u00e3o MQ, Souza Lima A, Wilson SE. Topical Losartan for treating corneal fibrosis (haze): first clinical experience. J Refract Surg. 2022;38(11):741\u20136.","journal-title":"J Refract Surg"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-025-07419-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:03:32Z","timestamp":1761573812000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-025-07419-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7419"],"URL":"https:\/\/doi.org\/10.1186\/s13104-025-07419-5","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the Declaration of Helsinki. Ethical approval for this study was granted by the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1400.204). Written informed consent was obtained from all individual participants included in the study. This study was supported by Shiraz University of Medical Sciences (Grant# 22845).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}